MS Speaks

Presented at the annual ACTRIMS conference (February 24-26), "Real-world comparative effectiveness and persistence of cladribine tablets and other oral disease-modifying treatments for multiple sclerosis from GLIMPSE: Results from the MSBase Registry":


https://www.abstractsonline.com/pp8/#!/10495/presentation/393


MedPage Today  has an article about this presentation (March 1), "MS patients on cladribine show fewer relapses":


https://bit.ly/35jTvnz


At the bottom of the MedPage Today article there is this notation:

Data collection and analysis were sponsored by Merck KGaA (EMD Serono).[/size]

Quote

Merck makes cladribine (Mavenclad).